1. Anticancer chemotherapy (including molecular targeted drugs), immunotherapy, or investigational agents within 7 days of the first dose of DSP-7888; radiotherapy within 4 weeks of the first dose of DSP-7888. Subjects may begin DSP-7888 on a date determined by the Investigator and medical monitor for the Sponsor provided that all treatment related adverse events (AEs) have resolved or have been deemed irreversible. This exclusion is not applied to subjects who meet the inclusion criterion 1d.